About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDNA

Study of Attention and Memory Treatments for Cancer Survivors

A Pilot Study of A Novel Cognitive Intervention for Cancer Survivors

NCT04870320•University of California, San Francisco

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm

Interventions

Endeavor: Computer-Based Cognitive Stimulation Intervention

Words!: Computer-Based Cognitive Stimulation Intervention

+1 more

Locations

1

United States

Locations (1)

University of California San Francisco

San Francisco, California, United States

Key Dates

Start Date

March 1, 2021

Primary Completion Date

January 31, 2022

Completion Date

January 31, 2022

Last Updated

April 8, 2022

Related Studies

RECRUITINGPhase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276

Malignant Female Reproductive System NeoplasmMalignant Solid Neoplasm+2 more

RECRUITINGPhase 1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

RECRUITINGPhase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

RECRUITINGPhase 2

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

RECRUITINGPhase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

RECRUITINGPhase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

View all related studies

Sponsors

Lead Sponsor

University of California, San Francisco

Collaborators

Akili Interactive Labs, Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions